MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a cardiomyopathy research deal set to expire in June 2025.

As Bristol Myers Squibb rolls ahead with its plan to cut $1.5 billion in costs by the end of the year, the drugmaker is once ...

Bristol-Myers Squibb has declared a $0.62 dividend per share on common stock, reaffirming its commitment to shareholder value ...

Bristol-Myers Squibb Company (NYSE:BMY) 45th Annual TD Cowen Health Care Conference March 4, 2025 2:30 PM ETCompany ParticipantsAdam Lenkowsky - ...

In October, the FDA approved Bristol Myers’ Opdivo for resectable NSCLC and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase (ALK) rearrangements, for ...

"Sandy's leadership has been instrumental in shaping Bristol Myers Squibb into the innovative and patient-focused organization it is today. The company is grateful for her leadership and ...

Bristol Myers Squibb has bolstered its case for Opdivo to be used as a preoperative treatment for non-small cell lung cancer (NSCLC) as it has delivered an overall survival (OS) edge when added to ...

Patient assistance programs (PAPs ... the majority of disease funds spent are in the form of other categories of assistance, not the purchasing of donor drugs. Given that HHS OIG’s opinion ...

Already imprisoned for 100 years, the self-proclaimed "serial killer" who dubbed himself after Halloween slasher Michael Myers on the stand is now facing more than 150 additional years behind bars ...

The outcome is likely to reshape the very foundation of U.S. foreign assistance. We have a bipartisan and urgent recommendation for policymakers in the Beltway: Artificial intelligence must become ...

Bristol Myers (BMY) Squibb announced new five-year ... Sotyktu remained consistent through five years with more than 5,000 patient-years of exposure in the trial, with no new safety signals ...